基于2009 H1N1神经氨酸酶天然产物抑制剂的作用模式的研究

doi:10.5246/jcps.2020.06.037

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (6): 390-397.DOI: 10.5246/jcps.2020.06.037

基于2009 H1N1神经氨酸酶天然产物抑制剂的作用模式的研究

靳玉瑞, 李爱秀^*, 康家雄

中国人民武装警察部队后勤学院基础部数理教研室, 天津 300309

收稿日期:2019-12-24 修回日期:2020-01-12 出版日期:2020-06-30 发布日期:2020-03-18
通讯作者: Tel.: +86-22-84876331, E-mail: liaixiu2008@126.com
基金资助:
National Nature Science Foundation of China (Grant No. 81241114), Basic Research Project of Logistics University of PAP (Grant No. WHJ201401), and Fund for Scientific Research and Innovation Team of Logistics University of PAP.

Insights from investigating the interactions of natural product inhibitors with neuraminidase of the 2009 H1N1 influenza virus

Yurui Jin, Aixiu Li^*, Jiaxiong Kang

Mathematics and Physics Section, Basic Science Department, Logistics University of People’s Armed Police Force, Tianjin 300309, China

Received:2019-12-24 Revised:2020-01-12 Online:2020-06-30 Published:2020-03-18
Contact: Tel.: +86-22-84876331, E-mail: liaixiu2008@126.com
Supported by:
National Nature Science Foundation of China (Grant No. 81241114), Basic Research Project of Logistics University of PAP (Grant No. WHJ201401), and Fund for Scientific Research and Innovation Team of Logistics University of PAP.

摘要/Abstract

摘要：

神经氨酸酶(NA)在流感病毒的复制过程中发挥关键作用, 临床上应用最多的抗流感病毒药物均为NA抑制剂(NAIs)。当前流行的2009 H1N1流感病毒的NA(09N1)与其他亚型NA的底物结合空腔存在差异, 故以09N1结构为基础开发对09N1高效的抑制剂更为适宜。由于天然产物的结构多样, 分析天然产物抑制剂与09N1的作用模式可为新型抑制剂的发现提供思路。本研究利用GOLD软件对10个天然产物NAIs与09N1进行了分子对接研究, 并首次获得它们与09N1的结合模式。对接结果表明, 活性位点S1区对于NAIs同09N1的结合非常重要, 从这些NAIs中抽提出5个与S1区发生作用的结构骨架, 可用于新型抑制剂的结构设计。此外还发现, 增强同活性位点的氢键作用可提高NAIs的抑制活性, 这可能是上市药物具有更高活性的原因。在09N1的活性空腔中发现同上市药物扎那米韦无相互作用的两处末端疏水位点(Terminal 1和Terminal 2), 并首次揭示4个天然产物能结合于该位点。迄今为止, 关于Terminal 2对于NAI与NA结合意义的研究还鲜见报道, 可作为NAIs合理药物设计研究的新方向。

关键词: 2009 H1N1流感病毒, 神经氨酸酶, 抑制剂, 天然产物, 分子对接

Abstract:

Neuraminidase (NA) plays a biologically vital role in the replication of influenza virus, and NA inhibitors (NAIs) are most widely used in the clinical anti-flu therapy. NA of 2009 H1N1 influenza virus (09N1) possesses a different substrate-binding cavity compared with other NA subtypes, making 09N1 a more appropriate starting point for the discovery of potent 09N1 inhibitors. As natural products are of great structural diversity, research on the interaction between natural NAIs and 09N1 can throw light on the design of new structural NAIs. In this study, we, for the first time, conducted molecular docking procedure with GOLD on 10 natural inhibitors to 09N1, and acquired their binding modes with 09N1. The docking results showed that the active site S1 was important in the binding of NAIs to 09N1. Then five scaffolds were extracted from these NAIs with interactions to site S1, and these could be used in the structural modification of NAIs. Besides, we found that the addition of H-bonding interaction with the active site could improve the NA inhibitory activity of NAIs, and it might be the reason why the approved NAIs showed high efficiency. Two terminal hydrophobic sites (Terminal 1 and Terminal 2) with no interactions to the approved NAI zanamivir were found in the 09N1 active cavity, and four NAIs were first found to bind with the terminals. Till now, there are few studies on the meaning of Terminal 2 in the binding of NAI to NA, which could be a new direction for the rational design of NAIs.

Key words: 2009 H1N1 influenza virus, Neuraminidase, Inhibitor, Natural product, Molecular docking

中图分类号:

R914.2

Supporting:

靳玉瑞, 李爱秀, 康家雄. 基于2009 H1N1神经氨酸酶天然产物抑制剂的作用模式的研究[J]. 中国药学(英文版), 2020, 29(6): 390-397.

Yurui Jin, Aixiu Li, Jiaxiong Kang. Insights from investigating the interactions of natural product inhibitors with neuraminidase of the 2009 H1N1 influenza virus[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 390-397.

参考文献

[1] Colman, P.M.; Varghese, J.N.; Laver, W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983, 303, 41-44.

[2] Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P.; Blackburn, G.M.; Hay, A.J.; Gamblin, S.J.; Skehel, J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006, 443, 45-49.

[3] Li, Q.; Qi, J.X.; Zhang, W.; Vavricka, C.J.; Shi, Y.; Wei, J.H.; Feng, E.G.; Shen, J.S.; Chen, J.L.; Liu, D.; He, J.H.; Yan, J.H.; Liu, H.; Jiang, H.L.; Teng, M.K.; Li, X.B.; Gao, G.F. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat. Struct. Mol. Biol. 2010, 17, 1266-1268.

[4] Lee, N.; Hurt, A.C. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr. Opin. Infect. Dis. 2018, 31, 520-526.

[5] Stoll, V.; Stewart, K.D.; Maring, C.J.; Muchmore, S.; Giranda, V.; Gu, Y.G.; Wang, G.; Chen, Y.W.; Sun, M.H.; Zhao, C.; Kennedy, A.L.; Madigan, D.L.; Xu, Y.B.; Saldivar, A.; Kati, W.; Laver, G.; Sowin, T.; Sham, H.L.; Greer, J.; Kempf, D. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry. 2003, 42, 718-727.

[6] Grienke, U.; Schmidtke, M.; Kirchmair, J.; Pfarr, K.; Wutzler, P.; Dürrwald, R.; Wolber, G.; Liedl, K.R.; Stuppner, H.; Rollinger, J.M. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J. Med. Chem. 2010, 53, 778-786.

[7] Amaro, R.E.; Minh, D.D.; Cheng, L.S.; Lindstrom, W.M. Jr, Olson, A.J.; Lin, J.H.; Li, W.W.; McCammon, J.A. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J. Am. Chem. Soc. 2007, 129, 7764-7765.

[8] Wang, M.Y.; Qi, J.X.; Liu, Y.; Vavricka, C.J.; Wu, Y.; Li, Q.; Gao, G.F. Influenza A virus N5 neuraminidase has an extended 150-cavity. J. Virol. 2011, 85, 8431-8435.

[9] Rudrawar, S.; Dyason, J.C.; Rameix-Welti, M.A.; Rose, F.J.; Kerry, P.S.; Russell, R.J.; van der Werf, S.; Thomson, R.J.; Naffakh, N.; von Itzstein, M. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat. Commun. 2010, 1, 113.

[10] Feng, E.G.; Shin, W.J.; Zhu, X.L.; Li, J.; Ye, D.J.; Wang, J.; Zheng, M.Y.; Zuo, J.P.; No, K.T.; Liu, X.; Zhu, W.L.; Tang, W.; Seong, B.L.; Jiang, H.L.; Liu, H. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors. J. Med. Chem. 2013, 56, 671-684.

[11] Singh, N.; Anjum, N.; Chandra, R. Combating influenza: natural products as neuraminidase inhibitors. Phytochem. Rev. 2019, 18, 69-107.

[12] Kirchmair, J.; Rollinger, J.M.; Liedl, K.R.; Seidel, N.; Krumbholz, A.; Schmidtke, M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med. Chem. 2011, 3, 437-450.

[13] Dao, T.T.; Nguyen, P.H.; Lee, H.S.; Kim, E.; Park, J.; Lim, S.I.; Oh, W.K. Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg. Med. Chem. Lett. 2011, 21, 294-298.

[14] Dao, T.T.; Nguyen, P.H.; Won, H.K.; Kim, E.H.; Park, J.; Won, B.Y.; Oh, W.K. Curcuminoids from Curcuma longa and their inhibitory activities on influenza A neuraminidases. Food Chem. 2012, 134, 21-28.

[15] Jin, Y.; Li, A.; Deng, L.; Luo, L.; Li, K. Molecular docking study based on 2009 H1N1 influenza neuraminidase. Comput. Appl. Chem. 2014, 31, 298-302.

基于2009 H1N1神经氨酸酶天然产物抑制剂的作用模式的研究

Insights from investigating the interactions of natural product inhibitors with neuraminidase of the 2009 H1N1 influenza virus

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	尚平, 刘琳, 方毅. 基于网络药理学和分子对接探讨桂枝茯苓丸治疗子宫内膜异位症的作用机制[J]. 中国药学(英文版), 2023, 32(9): 704-719.
[2]	迟骁玮, 黎奇, 钟毅, 龚桐, 衣楚潇, 张亮仁, 刘振明. 基于虚拟筛选发现潜在的黄嘌呤氧化酶抑制剂[J]. 中国药学(英文版), 2023, 32(8): 626-635.
[3]	朱玉霞, 张玲建, 胡懿鸣, 刘卫华, 关丽萍, 林琳. 海洋中药厚藤中柚皮素(naringenin)衍生物合成及胆碱酯酶抑制活性研究[J]. 中国药学(英文版), 2023, 32(8): 636-644.
[4]	武东燕, 王小丹, 柴金苗, 李钦青, 李悦, 毕梅, 桂婉威, 曹慧敏. 基于网络药理学及实验验证探究当归补血汤治疗糖尿病性视网膜病变的作用机制[J]. 中国药学(英文版), 2023, 32(7): 527-538.
[5]	敖民, 包明兰, 侯亚星, 月英, 李慧芳, 吴国华, 苏日嘎拉图. 基于网络药理学的蒙药肋柱花抗急性肝损伤作用机制研究[J]. 中国药学(英文版), 2023, 32(4): 268-282.
[6]	吴崇昊, 黄攀杰, 杨春琦, 高川, 曾鸣. 恶性胸膜间皮瘤免疫检查点抑制剂疗效及安全性meta分析[J]. 中国药学(英文版), 2023, 32(4): 291-301.
[7]	李晓辉, 王倩, 刘琛楠, 韩江雪, 刘思含, 刘天俊, 王倩, 关艳, 肖春玲, 王潇, 刘忆霜. 一种新型KPC-2抑制剂: PHT427[J]. 中国药学(英文版), 2023, 32(12): 989-997.
[8]	李雅静, 白雅雯, 杜宇, 严长宏, 麻春杰, 孙丽宁, 卜凤跃, 严昊阳. 玉屏风散治疗慢性肾小球肾炎的临床疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(12): 1006-1026.
[9]	孙志勇, 高淑丽, 张阳, 薛刚强, 苑子林, 王少男. 基于网络药理学和分子对接技术研究蒲公英治疗乳腺增生的潜在机制[J]. 中国药学(英文版), 2023, 32(11): 893-910.
[10]	周代英, 陈靓, 吕志刚. 基于网络药理学和分子对接探讨灯盏细辛治疗年龄相关性黄斑变性的机制[J]. 中国药学(英文版), 2023, 32(11): 923-934.
[11]	丁宁, 张涛, 罗吉, 刘皓辰, 邓宇, 何永恒. 基于网络药理学和分子对接探究白芍七物汤治疗结直肠癌的作用机制[J]. 中国药学(英文版), 2023, 32(1): 17-31.
[12]	付颖, 刘思默, 马燕, 吴南楠. 钠-葡萄糖共转运蛋白2抑制剂卡格列净在2型糖尿病治疗中的新进展[J]. 中国药学(英文版), 2022, 31(8): 569-588.
[13]	刘文彬, 刘东, 王雪, 杨照亮, 何筠, 杨杨. 奥司他韦修饰纳米金棒快速可视化检测流感病毒[J]. 中国药学(英文版), 2022, 31(7): 491-498.
[14]	伊帕尔古丽·阿皮孜, 王昭志, 贺宏吉, 李喆喆, 王梅. 基于网络药理学和分子对接探讨骆驼蓬种子抗肝癌作用机制[J]. 中国药学(英文版), 2022, 31(7): 517-529.
[15]	商燕, 蔺晓源, 张田田, 谢丽华, 胡国恒. 基于网络药理学和分子对接探讨益气活血方抗脑缺血机制研究[J]. 中国药学(英文版), 2022, 31(2): 117-133.